Abstract Library

#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)

Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,

Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,

#2742 Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents

Introduction: One of the main consequences of inhibition of neovessel growth produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for invasion. Particularly, anti-VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous mouse model of pancreatic neuroendocrine cancer, RIP1-Tag2.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Casanovas O

Authors: Zuazo-Gaztelu I, Pàez-Ribes M, Carrasco P, Martín-Mitjana L, Sallaberry J,

Keywords: Antiangiogenic therapies, Semaphorin 4D, Mouse models of NETs, Invasion and metastasis,

#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms

Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Apostolidis L

Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,

Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,

#2168 Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors

Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan J, Faris J, Murphy J, Blaszkowsky L, McCleary N,

Keywords: cabozantinib, pancreatic neuroendocrine tumor, carcinoid, phase II,

#2012 Expression and Clinical Significance of Vascular Endothelial Growth Factor D in Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: The expression of vascular endothelial growth factor D (VEGF-D) in tumor cells versus stroma cells in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and its clinical significance is still unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zhang Y

Authors: Zhang Y, Chen L, Lin Y, Chen M, Chen J,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, vascular endothelial growth factor D, expression, clinical significance,